Skip to main content
SpringerLink
Log in

Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain

  • Original Articles
  • Pharmacokinetics, Chlorambuciltertiary Butyl Ester, Chlorambucil, Brain
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Equimolar doses of chlorambucil (10 mg/kg) and the lipophilic chlorambucil derivative, chlorambuciltertiary butyl ester (13 mg/kg), were given i. v. to rats. Plasma and brain concentrations of chlorambucil and its active metabolites, 3,4-dehydrochlorambucil and phenylacetic mustard, as well as of chlorambucil-tertiary butyl ester were then determined by HPLC between 2 and 240 min after drug administration. Chlorambucil demonstrated a monophasic disappearance from plasma following its administration, with a half-life of 28 min. Significant amounts of phenylacetic mustard were detected after 15 min, and this agent maintained high levels of active compounds in plasma throughout the study. Only low concentrations of chlorambucil and phenylacetic mustard were detected in brain between 2 and 120 min. Following equimolar chlorambucil-tertiary butyl ester administration, it rapidly disappeared from plasma, with a half-life of approximately 2 min, and maintained low plateau concentrations between 15 and 120 min after treatment. It was not detected thereafter, although significant amounts of chlorambucil and phenylacetic mustard were detected throughout the study. Significant amounts of chlorambucil-tertiary butyl ester entered and remained within the brain, achieving a peak concentration at 15 min and disappearing thereafter with a half-life of 37 min. Low levels of chlorambucil and phenylacetic mustard were also detected. Calculated from the areas under the concentration vs time curves of total active compounds derived from chlorambucil and chlorambucil-tertiary butyl ester in brain and plasma, the brain: plasma concentration integral ratios were 0.018 and 0.68, respectively. Following equimolar doses of chlorambucil and chlorambucil-tertiary butyl ester, a 7-fold greater concentration integral was achieved by chlorambucil-tertiary butyl ester in brain at a 5-fold lower plasma concentration integral. Chlorambucil-tertiary butyl ester may be of value in the treatment of brain-sequestered tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aldridge WN (1953) Serum esterases: 1. Two types of esterase (A and B) hydrolysingp-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J 53: 110–117

    Google Scholar 

  2. Anderson J, Christensen L, Krogshlom H (1984) Phase II trial of prednimustine in glioblastoma multiforme. Cancer Treat Rep 68: 795–797

    Google Scholar 

  3. Annegers JF, Schoenberg BS, Okazaki H, Kurland LT (1981) Epidemiological study of primary intracranial neoplasms. Arch Neurol 38: 217–219

    Google Scholar 

  4. Augustinsson KB (1959) Electrophoresis studies on blood plasma esterases. Acta Chem Scand 13: 571–592

    Google Scholar 

  5. Augustinsson KB (1961) Multiple forms of esterase in vertebrate blood plasma. Ann NY Acad Sci 94: 844–860

    Google Scholar 

  6. Bodor N, Brewster M (1982) Problems of drug delivery to the brain. Pharmacol Ther 19: 337–386

    Google Scholar 

  7. Boyer PD (1971) The enzymes, vol 5. Academic, New York

    Google Scholar 

  8. Carter SK, Bakowski MT, Hellmann K (1987) Chemotherapy of cancer, 3rd edn. Wiley Medical, New York

    Google Scholar 

  9. Crawford J, Cohen HJ (1987) Relationship of cancer and aging. Clin Geriatr Med 3: 419–432

    Google Scholar 

  10. Davis DL, Schwartz J (1988) Trends in cancer mortality: US white males and females. Lancet: 633–636

  11. Dorr R, Fritz W (1980) Cancer chemotherapy handbook. Kimpton, London

    Google Scholar 

  12. Friedman HS, Schold SC, Bigner DD (1986) Chemotherapy of subcutaneous and intracerebral human medulloblastoma xenografts in athymic nude mice. Cancer Res 46: 224–228

    Google Scholar 

  13. Godeneche D, Madelmont J, Moreau M, Plagne R, Meyniel G (1980) Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards. Cancer Chemother Pharmacol 5: 1–9

    Google Scholar 

  14. Greig NH (1984) Chemotherapy of brain metastases: current status. Cancer Treat Rev 11: 157–180

    Google Scholar 

  15. Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1–28

    Google Scholar 

  16. Greig NH (1989) Brain tumors and the blood-tumor barrier. In: Neuwelt E (ed) Implications of the blood-brain barrier and its manipulation, vol 2. Plenum Press, NY, pp 77–106

    Google Scholar 

  17. Greig NH (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 1. Plenum Press, NY, pp 311–367

    Google Scholar 

  18. Greig NH, Rapoport SI (1988) Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother Pharmacol 21: 1–8

    Google Scholar 

  19. Greig NH, Momma S, Sweeney DJ, Smith QR, Rapoport SI (1987) Facilitated transport of melphalan at the rat bloodbrain barrier by the large neutral amino acid carrier system. Cancer Res 47: 1571–1576

    Google Scholar 

  20. Greig NH, Fredericks WR, Holloway HW, Soncrant TT, Rapoport SI (1988) Delivery of interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J Pharmacol Exp Ther 245: 581–586

    Google Scholar 

  21. Greig NH, Soncrant TT, Wozniak KM, Rapoport SI (1988) Plasma and tissue pharmacokinetics of human interferonalpha in the rat after its intravenous administration. J Pharmacol Exp Ther 245: 574–580

    Google Scholar 

  22. Greig NH, Daly EM, Rapoport SI (1989) Physicochemical and pharmacokinetics parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol 25: 311

    Google Scholar 

  23. Grossman S, Burch P, Brundrett R (1988) Chlorambucil delivery and retention in brain using the brain specific chemical delivery system: a quantitative autoradiographic study. Proc Am Assoc Cancer Res 29: 508

    Google Scholar 

  24. Hildebrand J (1985) Current status of chemotherapy of brain tumours. Progr Exp Tumor Res 29: 152–166

    Google Scholar 

  25. Johns DG, Farquhar D, Wolpert MK, Chabner BA, Loo TL (1973) Dialkyl esters of methotrexate and 3′–5′-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase. Drug Metab Dispos 3: 580–589

    Google Scholar 

  26. Kapetanovic IM, Sweeney DJ, Rapoport SI (1982) Age effects of haloperidol pharmacokinetics in male Fischer-344 rats. J Pharmacol Exp Ther 221: 434–438

    Google Scholar 

  27. Lee FYF, Coe P, Workman P (1986) Pharmacokinetic basis for the comparative antitumor activity and toxicity of chlorambucil, phenylacetic mustard andB,B-difluorochlorambucil (CB 7103) in mice. Cancer Chemother Pharmacol 17: 21–29

    Google Scholar 

  28. Marquardt D (1963) An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math 11: 431–441

    Google Scholar 

  29. Miller R (1966) Simultaneous statistical inference. McGraw-Hill, New York, pp 76–81

    Google Scholar 

  30. Neuwelt EA (1984) Therapeutic potential for blood-brain barrier modification in malignant brain tumor. Progr Exp Tumor Res 28: 51–66

    Google Scholar 

  31. Newell DR, Shepherd CR, Harrap KR (1981) The pharmacokinetics of prednimustine and chlorambucil in the rat. Cancer Chemother Pharmacol 6: 85–91

    Google Scholar 

  32. Oliverio V (1976) Pharmacology of the nitrosoureas: an overview. Cancer Treat Rep 60: 703–707

    Google Scholar 

  33. Posner J (1977) Management of central nervous system metastases. Semin Oncol 4: 81–89

    Google Scholar 

  34. Rapoport S (1976) Blood-brain barrier in physiology and medicine. Raven, New York

    Google Scholar 

  35. Roehrig GR, Billman JH, Marcec J, Fritz P, Shea F (1980) Synthesis and antitumor activity of 4-[p-[bis(2-chloroethyl)-amino]phenyl]butyrates. J Pharm Sci 69: 1232–1234

    Google Scholar 

  36. Rosowsky A, Abelson H, Beardsley G (1982) Pharmacological studies on the dibutyl and monobutyl esters of methotrexate in the rhesus monkey. Cancer Chemother Pharmacol 10: 55–61

    Google Scholar 

  37. Rosowsky A, Forsch R, Yu C (1984) Methotrexate analogues: 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monesters. J Med Chem 27: 605–609

    Google Scholar 

  38. Ross WJC (1962) Biological alkylating agents. Butterworths, London

    Google Scholar 

  39. Sheridan MA, Nines RG, Riblet SM, Finfrock MF, Trigg NJ, Houchens DP (1986) Glioma and medulloblastoma xenografts as models for brain tumor development. Proc Am Assoc Cancer Res 27: 385

    Google Scholar 

  40. Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence, Hamilton, Illinois, p 64

    Google Scholar 

  41. Walker AE, Robins M, Weinfeld FD (1985) Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35: 219–226

    Google Scholar 

  42. Walker M (1977) Treatment of brain tumors. Med Clin North Am 61: 1045–1051

    Google Scholar 

  43. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–1329

    Google Scholar 

  44. Werner MH, Schold SC (1987) Primary intracranial neoplasms in the elderly. Clin Geriatr Med 3: 765–779

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neurosciences, National Institutes on Aging, National Institutes of Health, Bldg. 10, Rm 6C 103, 20892, Bethesda, MD, USA

    Nigel H. Greig, Eileen M. Daly, Daniel J. Sweeney & Stanley I. Rapoport

Authors
  1. Nigel H. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eileen M. Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel J. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stanley I. Rapoport
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greig, N.H., Daly, E.M., Sweeney, D.J. et al. Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother. Pharmacol. 25, 320–325 (1990). https://doi.org/10.1007/BF00686230

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686230

Keywords

Search

Navigation